In vivo suppression of restenosis in balloon-injured rat carotid artery by adenovirus-mediated gene transfer of the cell surface-directed plasmin inhibitor ATF.BPTI

Gene Therapy

Volumn 8, Issue 7, 2001, Pages 534-541

  Lamfers, M L M ^a   Lardenoye, J H P ^a   De Vries, M R ^a   Aalders, M C ^a   Engelse, M A ^b   Grimbergen, J M ^a   Van Hinsbergh, V W M ^a   Quax, P H A ^a,c  

^a TNO   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Gene therapy; Neointima; Plasmin; SMC migration

Indexed keywords

APROTININ; HYBRID PROTEIN; MATRIX METALLOPROTEINASE; MATRIX PROTEIN; MESSENGER RNA; PLASMIN; PLASMIN INHIBITOR; UROKINASE; UROKINASE RECEPTOR; VIRUS VECTOR;

ADENOVIRUS; AMINO TERMINAL SEQUENCE; ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; ARTERY INJURY; ARTERY INTIMA; ARTERY MEDIA; ARTICLE; BLOOD VESSEL WALL; CAROTID ARTERY; CELL MIGRATION; CELL PROLIFERATION; CELL SURFACE; CHO CELL; CONTROLLED STUDY; DRUG POTENCY; ENZYME ACTIVATION; ENZYME INHIBITION; EXTRACELLULAR MATRIX; GENE CONSTRUCT; GENE TARGETING; GENE TRANSFER; GENETIC CODE; IN VITRO STUDY; IN VIVO STUDY; INFECTION; INHIBITION KINETICS; MALE; MORPHOMETRICS; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; RECEPTOR BINDING; RESTENOSIS; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ADENOVIRIDAE; ANGIOPLASTY, BALLOON; ANIMALS; APROTININ; CAROTID ARTERIES; CAROTID STENOSIS; CELL CULTURE TECHNIQUES; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; MALE; PEPTIDE FRAGMENTS; PLASMIN; RATS; RATS, SPRAGUE-DAWLEY; RECURRENCE; RNA, MESSENGER; TUNICA INTIMA; TUNICA MEDIA; URINARY PLASMINOGEN ACTIVATOR;

ADENOVIRIDAE; ANIMALIA; BOVINAE;

EID: 0035041170     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301437     Document Type: Article

References (50)

1. Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty
2. The pathogenesis of atherosclerosis: A perspective for the 1990s
3. Extracellular matrix collagen synthesis and degradation following coronary balloon angioplasty
4. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty
5. Adenoviral RB2/p130 gene transfer inhibits smooth muscle cell proliferation and prevents restenosis after angioplasty
6. Adenovirus-mediated transfer of a dominant-negative H-ras suppresses neointimal formation in balloon-injured arteries in vivo
7. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia
8. Percutaneous delivery of the gax gene inhibits vessel stenosis in a rabbit model of balloon angioplasty
9. The effect of oligonucleotides to c-myb on vascular smooth muscle cell proliferation and neointima formation after porcine coronary angioplasty
10. E2f decoy oligonucleotide for genetic engineering of vascular bypass grafts
11. Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease
12. Gene therapy for vascular smooth muscle cell proliferation after arterial injury
13. Inhibition of vascular smooth muscle cell proliferation and neointimal accumulation by adenovirus-mediated gene transfer of cytosine deaminase
14. Antisense basic fibroblast growth factor gene transfer reduces neointimal thickening after arterial injury
15. Local adenoviral-mediated expression of recombinant hirudin reduces neointima formation after arterial injury
16. Inhibition of cell surface receptor-bound plasmin by alpha 2- antiplasmin and alpha 2-macroglobulin
17. The migration of human smooth muscle cells in vitro is mediated by plasminogen activation and can be inhibited by alpha2-macroglobulin receptor associated protein
18. Contrasting effects of plasminogen activators, urokinase receptor, and LDL receptor-related protein on smooth muscle cell migration and invasion
19. Urokinase and tissue-type plasminogen activator are required for the mitogenic and chemotactic effects of bovine fibroblast growth factor and platelet-derived growth factor-BB for vascular smooth muscle cells
20. Migration of arterial wall cells. Expression of plasminogen activators and inhibitors in injured rat arteries
21. The role of plasminogen activation in smooth muscle cell migration after arterial injury
22. Prevention of neointimal formation by a serine protease inhibitor, FUT-175, after carotid balloon injury in rats
23. Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice
24. Impaired arterial neointima formation in mice with disruption of the plasminogen gene
25. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: A gene targeting and gene transfer study in mice
26. Adenoviral gene transfer of a u-PA receptor-binding plasmin inhibitor and green fluorescent protein: Inhibition of migration and visualization of expression
27. Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium
28. Inhibitors of fibrinolysis are elevated in atherosclerotic plaque
29. Smooth muscle migration in atherosclerosis and restenosis
30. Migration of smooth muscle and endothelial cells. Critical events in restenosis
31. Significance of quiescent smooth muscle migration in the injured rat carotid artery
32. Mitogen crosstalk accompanying urokinase receptor expression in stimulated vascular smooth muscle cells
33. The plasminogen activator/plasmin system
34. The cell biology of the plasminogen system
35. The urokinase receptor and regulation of cell surface plasminogen activation
36. Expression of tissue inhibitor of matrix metalloproteinases 1 by use of an adenoviral vector inhibits smooth muscle cell migration and reduces neointimal hyperplasia in the rat model of vascular balloon injury
37. Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo
38. Adenovirus-mediated gene transfer of the human tissue inhibitor of metalloproteinase-2 blocks vascular smooth muscle cell invasiveness in vitro and modulates neointimal development in vivo
39. Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes
40. Control of type IV collagenase activity by components of the urokinase-plasmin system: A regulatory mechanism with cell-bound reactants
41. Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury
42. The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases
43. Binding of human urokinase-type plasminogen activator to its receptor - Residues involved in species specificity and binding
44. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses
45. Complementation between urokinase-producíng and receptor-producing cells in extracellular matrix degradation
46. Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles
47. Mechanisms of stenosis after arterial injury
48. In vivo gene transfer into injured carotid arteries. Optimization and evaluation of acute toxicity
49. Strong induction of members of the chitinase family of proteins in atherosclerosis: Chitotriosidase and human cartilage gp-39 expressed in lesion macrophages
50. Cooperative effect of TNFalpha, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity